2024 greatest T1D hits: A glance at this year’s achievements
While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures and improving everyday life with T1D. This wouldn’t have been possible without each and every one of you and your continued support of our mission as we drive toward cures for T1D. Here are the […]
Breakthrough T1D shares the latest research at ISPAD
At the 2024 International Society for Pediatric and Adolescent Diabetes (ISPAD) Conference in Lisbon, Portugal, the world’s leading diabetes researchers, academics, and members of industry gathered to share the latest and greatest in diabetes research. Breakthrough T1D leaders and many of our funded researchers and collaborators were on hand —for ISPAD’s 50th birthday—to share new […]
Breakthrough T1D and the Nobel Prizes: Connected!
It’s early October, which means the Nobel Prizes are being awarded in several categories. These prestigious awards recognize outstanding contributions in Peace, Literature, Physics, Chemistry, Physiology or Medicine, and Economic Sciences. They go to the best and brightest people with the best and brightest ideas. This year, the prizes recognize work that is, in several […]
Powering research breakthroughs
We invest in the most promising research to turn ideas into life-changing therapies and lead the way to cures.
What Drug Will Be the Next Tzield?
In 2023 alone, there have been several important papers published on disease-modifying therapies (DMT) for type 1 diabetes. This blog explains everything you need to know about several DMTs.
FDA-Approved Immune Therapy Shows Benefit in Newly Diagnosed
In a Breakthrough T1D-funded clinical trial and published in the New England Journal of Medicine, baricitinib preserved beta cell function in type 1 diabetes.
Results Are Out: Tzield Benefits Newly Diagnosed Individuals
A new study published in the New England Journal of Medicine shows Tzield can preserve beta cell health in certain individuals recently diagnosed with T1D.
Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
Breakthrough T1D & NIH Workshop at the Intersection of Immunology and Bioengineering
Breakthrough T1D and NIH bring together top scientists and engineers to strategize on how to allow implanted beta cells to thrive.
Teplizumab (the Therapy that Delays T1D By Nearly 3 Years) Isn’t Approved…Yet
The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning that it has not been approved at this time.
